Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 6

1.

A novel synthetic cannabinoid derivative inhibits inflammatory liver damage via negative cytokine regulation.

Lavon I, Sheinin T, Meilin S, Biton E, Weksler A, Efroni G, Bar-Joseph A, Fink G, Avraham A.

Mol Pharmacol. 2003 Dec;64(6):1334-41.

PMID:
14645663
2.

Interaction of dexanabinol (HU-211), a novel NMDA receptor antagonist, with the dopaminergic system.

Striem S, Bar-Joseph A, Berkovitch Y, Biegon A.

Eur J Pharmacol. 1997 Nov 12;338(3):205-13.

PMID:
9424014
3.

Protection against septic shock and suppression of tumor necrosis factor alpha and nitric oxide production by dexanabinol (HU-211), a nonpsychotropic cannabinoid.

Gallily R, Yamin A, Waksmann Y, Ovadia H, Weidenfeld J, Bar-Joseph A, Biegon A, Mechoulam R, Shohami E.

J Pharmacol Exp Ther. 1997 Nov;283(2):918-24.

PMID:
9353414
4.

HU-211, a nonpsychotropic cannabinoid, improves neurological signs and reduces brain damage after severe forebrain ischemia in rats.

Belayev L, Bar-Joseph A, Adamchik J, Biegon A.

Mol Chem Neuropathol. 1995 May;25(1):19-33.

PMID:
7546016
5.

Neuroprotective activity of HU-211, a novel NMDA antagonist, in global ischemia in gerbils.

Bar-Joseph A, Berkovitch Y, Adamchik J, Biegon A.

Mol Chem Neuropathol. 1994 Oct-Dec;23(2-3):125-35.

PMID:
7702703
6.

Anti-ischemia activity of HU-211, a non-psychotropic synthetic cannabinoid.

Vered M, Bar-Joseph A, Belayev L, Berkovich Y, Biegon A.

Acta Neurochir Suppl (Wien). 1994;60:335-7.

PMID:
7976583

Supplemental Content

Loading ...
Support Center